中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (12): 996-1000.doi: 10.19401/j.cnki.1007-3639.2017.12.014

• 综述 • 上一篇    

高迁移率族蛋白B1与肿瘤治疗抵抗相关机制的研究进展

林 宇1,贺思佳2,黄 倩2   

  1. 1. 上海交通大学附属第一人民医院临床医学院,上海 201620 ;
    2. 上海交通大学附属第一人民医院肿瘤中心,上海201620
  • 出版日期:2017-12-30 发布日期:2018-01-11
  • 通信作者: 黄 倩 E-mail:qianh2011@126.com
  • 基金资助:
    国家自然科学基金(81572951)。

Research progress of the correlation between HMGB1 and tumor therapy resistance

LIN Yu1, HE Sijia2, HUANG Qian2   

  1. 1. Clinical Medical College, the Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China; 2. Cancer Center, the Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China
  • Published:2017-12-30 Online:2018-01-11
  • Contact: HUANG Qian E-mail: qianh2011@126.com

摘要: 肿瘤是危害人类健康的一种重要疾病,也是造成人类死亡的重要原因之一。随着技术的进步,肿瘤治疗的手段已经不再局限于传统的手术治疗、化疗和放疗,免疫治疗和靶向治疗等新兴治疗手段也相继得到发展。虽然治疗肿瘤的手段众多,但是肿瘤治疗的效果却不尽人意。肿瘤治疗效果不佳与早期诊断困难、治疗不充分等因素有关,治疗抵抗的出现也给肿瘤治疗带来了极大的障碍。近年来,许多研究表明高迁移率族蛋白B1(high mobility group protein B1,HMGB1)与肿瘤治疗抵抗有着密切的联系。研究发现,HMGB1能通过参与细胞自噬、DNA损伤修复、抗细胞凋亡、促进细胞增殖、促进血管生成、促进免疫逃逸和促进炎性反应等机制而造成肿瘤细胞对各种治疗手段产生抵抗。该研究将就近年来关于HMGB1与肿瘤治疗抵抗相关机制的研究进展作一综述。

关键词: 高迁移率族蛋白B1, 肿瘤, 治疗抵抗

Abstract: Cancer is an important disease which jeopardizes people's health, and also one of the important causes of human death. With the progress of technology, the treatments of cancer are no longer limited to the surgical treatment, chemotherapy and traditional radiotherapy. Endocrine therapy, immunotherapy, targeted therapy and other novel therapeutic methods have also been developed. Although there are many therapies for cancer, the effect of cancer treatment is unsatisfactory. Poor therapeutic effect of cancer treatment is associated with difficulty of early diagnosis, deficiency of remedy and some other factors. Moreover, the emergence of resistance to the tumor treatment has also brought great obstacles to cancer therapy. In recent years, many studies have shown that there is a close relationship between high mobility group protein B1 (HMGB1) and tumor chemotherapy resistance. Some researchers have found that HMGB1 can promote tumor therapy resistance by participating in cell autophagy, DNA damage repair, resistance to cell apoptosis, promotion of cell proliferation and angiogenesis, enhancement of immune escape and inflammation. In this paper, the recent research progress of the correlation between HMGB1 and tumor therapy resistance were reviewed.

Key words: HMGB1, Neoplasm, Therapy resistance